TY - JOUR
T1 - Cancer Surveillance in Solid Organ Transplant Recipients With a Pretransplant History of Malignancy
T2 - Multidisciplinary Collaborative Expert Opinion
AU - Watt, Kymberly D.
AU - Rolak, Stacey
AU - Foley, David P.
AU - Plichta, Jennifer K.
AU - Pruthi, Sandhya
AU - Farr, Deborah
AU - Zwald, Fiona O.
AU - Carvajal, Richard D.
AU - Dudek, Arkadiusz Z.
AU - Sanger, Cristina B.
AU - Rocco, Ricciardi
AU - Chang, George J.
AU - Dizon, Don S.
AU - Langstraat, Carrie L.
AU - Teoh, Deanna
AU - Agarwal, Piyush K.
AU - Al-Qaoud, Talal
AU - Eggener, Scott
AU - Kennedy, Cassie C.
AU - D'cunha, Jonathan
AU - Mohindra, Nisha A.
AU - Stewart, Shelby
AU - Habermann, Thomas H.
AU - Schuster, Stephen
AU - Lunning, Matthew
AU - Shah, Nirav N.
AU - Gertz, Morie A.
AU - Mehta, Jayesh
AU - Suvannasankha, Attaya
AU - Verna, Elizabeth
AU - Farr, Maryjane
AU - Blosser, Christopher D.
AU - Hammel, Laura
AU - Al-Adra, David P.
N1 - Publisher Copyright:
© 2024 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2024/12/1
Y1 - 2024/12/1
N2 - With improved medical treatments, the prognosis for many malignancies has improved, and more patients are presenting for transplant evaluation with a history of treated cancer. Solid organ transplant (SOT) recipients with a prior malignancy are at higher risk of posttransplant recurrence or de novo malignancy, and they may require a cancer surveillance program that is individualized to their specific needs. There is a dearth of literature on optimal surveillance strategies specific to SOT recipients. A working group of transplant physicians and cancer-specific specialists met to provide expert opinion recommendations on optimal cancer surveillance after transplantation for patients with a history of malignancy. Surveillance strategies provided are mainly based on general population recurrence risk data, immunosuppression effects, and limited transplant-specific data and should be considered expert opinion based on current knowledge. Prospective studies of cancer-specific surveillance models in SOT recipients should be supported to inform posttransplant management of this high-risk population.
AB - With improved medical treatments, the prognosis for many malignancies has improved, and more patients are presenting for transplant evaluation with a history of treated cancer. Solid organ transplant (SOT) recipients with a prior malignancy are at higher risk of posttransplant recurrence or de novo malignancy, and they may require a cancer surveillance program that is individualized to their specific needs. There is a dearth of literature on optimal surveillance strategies specific to SOT recipients. A working group of transplant physicians and cancer-specific specialists met to provide expert opinion recommendations on optimal cancer surveillance after transplantation for patients with a history of malignancy. Surveillance strategies provided are mainly based on general population recurrence risk data, immunosuppression effects, and limited transplant-specific data and should be considered expert opinion based on current knowledge. Prospective studies of cancer-specific surveillance models in SOT recipients should be supported to inform posttransplant management of this high-risk population.
UR - http://www.scopus.com/inward/record.url?scp=85207752060&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85207752060&partnerID=8YFLogxK
U2 - 10.1097/tp.0000000000005056
DO - 10.1097/tp.0000000000005056
M3 - Review article
C2 - 38771067
AN - SCOPUS:85207752060
SN - 0041-1337
VL - 108
SP - 2336
EP - 2350
JO - Transplantation
JF - Transplantation
IS - 12
ER -